Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovaBay Pharmaceuticals (NBY) Gross Profit (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Gross Profit for 13 consecutive years, with $42000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gross Profit changed N/A to $42000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $3.1 million, a 29.83% decrease, with the full-year FY2024 number at $6.5 million, up 6.53% from a year prior.
  • Gross Profit was $42000.0 for Q3 2025 at NovaBay Pharmaceuticals, down from $1.5 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $2.4 million in Q3 2022 to a low of $42000.0 in Q3 2025.
  • A 5-year average of $1.6 million and a median of $1.6 million in 2021 define the central range for Gross Profit.
  • Peak YoY movement for Gross Profit: surged 76.32% in 2022, then crashed 38.29% in 2023.
  • NovaBay Pharmaceuticals' Gross Profit stood at $1.7 million in 2021, then grew by 4.59% to $1.8 million in 2022, then plummeted by 38.29% to $1.1 million in 2023, then skyrocketed by 38.69% to $1.5 million in 2024, then crashed by 97.2% to $42000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Gross Profit are $42000.0 (Q3 2025), $1.5 million (Q4 2024), and $1.6 million (Q2 2024).